Gyre Therapeutics 2025 Q3 Earnings Net Income Surges 107.8% to $5.94M

Gyre Therapeutics (GYRE) reported fiscal 2025 Q3 earnings on Nov 8, 2025, with revenue rising 19.9% to $30.56 million. The company exceeded net income expectations, posting $5.94 million (up 107.8% YoY), but revised full-year revenue guidance downward to $115–118 million due to Etorel rollout delays and procurement uncertainties.

Revenue

Gyre’s total revenue grew 19.9% year-over-year to $30.56 million, driven by strong performance across its portfolio. The Gyre Pharmaceuticals segment, which encompasses all commercial operations, contributed the entirety of this revenue, reflecting robust sales of ETUARY® and early traction from new launches like Etorel® and Contiva®.

Earnings/Net Income

Earnings per share (EPS) surged 300% to $0.04, with net income reaching $5.94 million—107.8% higher than $2.86 million in the prior-year period. This marked a significant improvement in profitability, underscoring the company’s effective cost management and commercial execution. The EPS growth aligns with the company’s strategic focus on expanding its product portfolio and optimizing operational efficiency.

Post-Earnings Price Action Review

The stock price of Gyre Therapeutics experienced a mixed post-earnings performance. During the latest trading day, shares edged down 0.83%, while the full trading week saw a steeper decline of 6.97%. Month-to-date, the stock retreated 1.23%. These movements reflect market skepticism around the revised revenue guidance and near-term execution risks, despite the strong net income results and improved liquidity.

CEO Commentary

Ping Zhang, Executive Chairman and Interim CEO, emphasized progress in China’s Hydronidone NDA submission and completed enrollment in the pirfenidone pneumoconiosis trial. He noted that the U.S. IND filing for Hydronidone is now targeted for 2026, pending data translation and a hepatic impairment study. Zhang highlighted ETUARY®’s continued growth and the need to navigate supply chain and procurement challenges for Etorel® and Contiva®.

Guidance

The company revised full-year 2025 revenue guidance to $115–118 million from $118–128 million, citing slower-than-expected commercialization of key products. No formal EPS guidance was provided, but management expressed confidence in ETUARY®’s momentum and the potential for Hydronidone’s regulatory milestones to drive long-term value.

Additional News

Gyre Therapeutics increased its indirect ownership in Gyre Pharmaceuticals to 69.7% via a capital contribution, strengthening control over its China-based operations. Ping Zhang was appointed Interim CEO, succeeding the previous leadership, signaling a strategic realignment. The company also announced plans to conduct a U.S. hepatic impairment study for Hydronidone, supporting its 2026 IND timeline. No dividend or share repurchase programs were disclosed in the earnings release.